PFE · News · 20261113N

Revenue Performance and Mix

PFIZER INC · 2026-11-13 · Importance 51 · Surprise 60 · In source text

Pfizer reported third-quarter 2026 revenue of $16.58 billion, flat year over year, and adjusted earnings of $0.87 per share. Growth in Eliquis, Padcev, the Vyndaqel family, Nurtec, and Lorbrena was offset by lower sales of COVID-19 products and the Prevnar family. The report also said strong year-to-date commercial performance prompted Pfizer to raise its full-year 2026 revenue and earnings guidance, without specifying the revised amounts.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenueunclearrealized0.0%Pfizer's third-quarter adjusted earnings were $0.87 per share and revenue was $16.58 billion, both flat year over year.